Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies
Objective: Chimeric antigen receptor-modified T (CAR-T) cells have shown impressive results against relapsed/refractory B cell malignancies. However, the traditional manufacture of CAR-T cells requires leukapheresis to isolate large amounts of peripheral blood T cells, thus making some patients inel...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
China Anti-Cancer Association
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/b31ae4dc1bc947628b4a687150159dd3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|